Celularity Inc's Customers Performance

Name: Celularity Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

CELU

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


CELU's Source of Revenues		During the corresponding time, Celularity Inc saw a revenue deteriorated by -77.37 % year on year, sequentially revenue fell by -22.33 %. While revenue at the Celularity Inc 's corporate clients • List of CELU Customers

for the same period Celularity Inc revnue deteriorated by -77.37 % year on year, sequentially revenue fell by -22.33 %.

• List of CELU Customers

Celularity Inc's Business Units


Product	16.92 %	of total Revenue
Processing and Storage Fees Net	27.4 %	of total Revenue
License Royalty and Other	55.68 %	of total Revenue
Cell Therapy	30.13 %	of total Revenue
BioBanking	27.4 %	of total Revenue
Degenerative Disease	69.72 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Celularity Inc's Comment on Sales, Marketing and Customers

News about Celularity Inc Contracts

Unleashing the Healing Power: Decellularized Placental Biomaterials for Tendon Injury Management

Tendon injuries are a significant cause of morbidity and reduced quality of life, affecting millions of people worldwide. Current treatment options often fall short in achieving optimal functional recovery, highlighting the need for innovative approaches. In recent years, emerging technologies in regenerative medicine have shown great promise in addressing the challenges associated with tendon injuries. Among these advancements, decellularized placental biomaterials have garnered significant attention for their remarkable potential in promoting tendon healing and protection. This article delves into the study presented by Celularity Inc. at the Orthopedic Research Society (ORS) Tendon Conference, shedding li...

Celularity's PDA-002 Shows Promise for Facioscapulohumeral Muscular Dystrophy: Seeks FDA's Orphan Drug Designation

Celularity Seeks Orphan Drug Designation for PDA-002 in Facioscapulohumeral Muscular Dystrophy TreatmentCelularity, a leading biotechnology company focused on the development of innovative cellular therapies, has recently announced that it has submitted a request to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation for its investigational asset, PDA-002. The company has already received Investigational New Drug (IND) clearance from the FDA and is planning to initiate a Phase 1/2 study in 2024, utilizing their off-the-shelf, placental-derived cell therapy.Facioscapulohumeral Muscular Dystrophy (FSHD) is a rare genetic disorder characterized by the progressive weakening and degeneration ...

Celularity Forecasts Stellar Growth in 2024: A Deep Dive into Advanced Biomaterial Product Business and Biobanking

In line with an impressive growth trajectory initiated in 2023, Celularity Inc. recently unveiled its net sales projections for the first quarter and the entire year of 2024. Notably, the company is expecting a triple-digit percentage surge in the combined net sales of its cutting-edge biomaterial product business and biobanking operations. This calculated anticipation is built upon a comparison with the financial performance of the first quarter and the full year of 2023.Founded on the powerful triad of cellular medicine, functional regeneration, and immuno-oncology, Celularity has been a pioneering force in leveraging the enormous potential of advanced biomaterials and biobanking sectors. The company s uni...

CELU's Stock Performance relative to it's Customers

CELU's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Celularity Inc	35.33	26.55	-91.80	120
SUBTOTAL	0.00	0.00	0.00	-

Sources: Celularity Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Celularity Inc’s corporate clients.
For your research, we’ve provided 9 tables on Celularity Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.